(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 May 2010 (14.05.2010)

PCT

(10) International Publication Number
WO 2010/052625 A1

(51) International Patent Classification:
C07D 207/16 (2006.01) *A61K 31/40* (2006.01)
C07D 401/12 (2006.01) *A61P 43/00* (2006.01)
C07D 403/12 (2006.01)

(21) International Application Number:
PCT/IB2009/054824

(22) International Filing Date:
30 October 2009 (30.10.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/112,869 10 November 2008 (10.11.2008) US

(71) Applicant *(for all designated States except US)*: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DACK, Kevin Neil** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **MILLS, James Edward John** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **SKERRATT, Sarah Elizabeth** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(74) Agent: **DROUIN, Stephane**; Pfizer Global Research and Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

(54) Title: PYRROLIDINES



(I)

(57) Abstract: This invention relates to a class of pyrrolidine compounds of formula (I), and pharmaceutical ly acceptable derivatives thereof, to their use in med icine, to compositions containing them, and to processes for their preparation. It also relates to intermediates used in the preparation of such compounds and derivatives. In particular the compounds of formula (I) are useful for the treatment of EP2-mediated conditions, such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), chronic pelvic pain syndrome, polycystic kidney disease and polycystic ovarian syndrome.

WO 2010/052625 A1